scispace - formally typeset
N

Nunzio Iraci

Researcher at University of Salerno

Publications -  52
Citations -  1775

Nunzio Iraci is an academic researcher from University of Salerno. The author has contributed to research in topics: Docking (molecular) & Integrase. The author has an hindex of 26, co-authored 52 publications receiving 1488 citations. Previous affiliations of Nunzio Iraci include Katholieke Universiteit Leuven & University of Perugia.

Papers
More filters
Journal ArticleDOI

Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity

TL;DR: A series of 2,2'-diselenobisbenzoic scaffold, amino acid, and benzenesulfonamide derivatives are identified as novel HIV retroviral nucleocapsid protein 7 (NCp7) inhibitors and their mechanism of action is based on NCp7 inhibition.
Journal ArticleDOI

Pharmacophore-Based Discovery of Small-Molecule Inhibitors of Protein–Protein Interactions between HIV-1 Integrase and Cellular Cofactor LEDGF/p75

TL;DR: This study finds a new and more potent small molecule that is able to interfere with the HIV‐1 IN–LEDGF/p75 interaction at micromolar concentration, representing one of the first compounds to show activity against these specific PPIs.
Journal ArticleDOI

A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model

TL;DR: This work shows, for the first time, complete suppression of viral load by highly intensified ART and a likely associated restriction of the viral reservoir in the macaque AIDS model, making it a useful platform for testing potential cures for AIDS.
Journal ArticleDOI

Pyrazolo[4,3-c][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of Staphylococcus aureus NorA Efflux Pump Inhibitors

TL;DR: The EPI activity of the COX-2 inhibitor celecoxib was confirmed and a new class of pyrazolo[4,3-c][1,2]benzothiazine 5,5-dioxide analogues acting as inhibitors of the Staphylococcus aureus NorA multidrug efflux pump was identified.
Journal ArticleDOI

Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.

TL;DR: The rational discovery of N(1)-arylsulfonyl-1,3-dihydro-2H-benzimidazol-2-one as a novel template for the design of new non-nucleoside reverse transcriptase inhibitors (NNRTIs) that are active against wild-type and mutant strains of HIV-1 was found.